Advocacy groups and bereaved relatives are condemning the British government’s newly established payout framework, alleging that the infected blood scandal compensation scheme creates a "penalty for dying" for the thousands of victims who did not survive to see the conclusion of the public inquiry. The controversy centers on a structural disparity in how financial losses are calculated, which advocates say leaves the estates of deceased victims with significantly lower settlements than those awarded to survivors.
Under the current rules, the scheme provides payouts to those who were infected with HIV or hepatitis through contaminated blood products administered by the National Health Service (NHS) between 1970 and 1996. While living victims are eligible for comprehensive awards covering projected future financial losses, the families of those who died before the scheme’s inception are being told that no such future loss will be recognized. This limitation has sparked a wave of criticism from charities and legal representatives who argue that the government is essentially devaluing the lives of those who perished as a direct result of state-sponsored medical negligence.
The infected blood scandal is widely regarded as the deadliest treatment disaster in the history of the NHS. More than 30,000 people in the United Kingdom were exposed to lethal viruses—including HIV, hepatitis B, and hepatitis C—after receiving blood transfusions or factor treatments derived from high-risk donor pools. To date, more than 3,000 victims have died from complications related to these infections, and the death toll continues to rise as aging survivors succumb to long-term organ damage and secondary cancers.
The Structural Disparity and the ‘Penalty for Dying’
The core of the grievance lies in the technical calculation of "financial loss" awards. Every person confirmed to have been infected is entitled to a base award of £12,500. However, the secondary "financial loss" component is intended to compensate for the earnings and economic stability lost due to the infection. For survivors, this calculation includes a projection of what they would have earned throughout their natural working life.
For the estates of the deceased, the government has restricted these calculations to the period between the date of infection and the date of death. In many instances, victims died within a few years of being infected, particularly during the height of the HIV/AIDS epidemic in the 1980s and early 1990s. By cutting off the financial loss calculation at the moment of death, the scheme excludes decades of potential earnings that would have supported the victims’ families and dependents.
Charities including the Haemophilia Society and the Hepatitis C Trust recently issued an open letter to the government, highlighting that a victim who died in their 30s during the 1990s loses out on nearly 50 years of recognized financial loss. The letter argues that the infected blood scandal compensation scheme effectively punishes families for the fact that their loved ones were unable to survive the very wrongdoing the compensation is intended to address.
Historical Context of the Contaminated Blood Crisis
The roots of this crisis trace back to the 1970s, when the UK began importing blood-clotting treatments, known as Factor VIII, from the United States. These products were often manufactured using plasma collected from high-risk donors, including prison inmates and intravenous drug users, who were paid for their blood. A single batch of Factor VIII could contain plasma from thousands of different donors, meaning a single contaminated sample could infect hundreds of patients.
Despite early warnings from medical experts about the risks of viral transmission, the NHS continued to use these products for years. Many patients, particularly those with hemophilia, were never informed of the risks, and in some cases, they were not told they had tested positive for HIV or hepatitis for years after the fact. This lack of transparency prevented victims from taking precautions to protect their partners and children, leading to secondary infections within families.
The Infected Blood Inquiry, chaired by Sir Brian Langstaff, was established in 2017 to investigate these systemic failures. After years of testimony from thousands of witnesses, the inquiry is scheduled to conclude its formal work on March 31. While the inquiry’s findings have provided a degree of moral closure for some, the focus has now shifted entirely to the adequacy and fairness of the resulting compensation framework.
A Multi-Generational Impact on Bereaved Families
The human cost of the "penalty for dying" is illustrated by the case of Jai Brahmbhatt, a university professor who moved from Kenya to the UK in 1972 seeking better treatment for his hemophilia. Instead, he was treated with contaminated blood products and died in 1993 at the age of 39. His daughter, Ami Jai Presly, who is now 39 herself, discovered that her father’s estate would only be compensated for 16 years of financial loss.
Presly and her sister, Meera Pierson, have been vocal about the emotional and economic shadow the scandal has cast over their lives. They argue that the current framework suggests their father’s life was worth less because he died decades ago. The sisters maintain that if their father had survived to the present day, the payout to the family would be roughly double what is currently being offered.
"The compensation framework is the only mechanism we have to talk about this," Presly said, noting that while money cannot replace a parent, it is the state’s only tool for acknowledging the magnitude of the loss. She described the current policy as "unethical and wrong," asserting that the government is taking advantage of the victims’ deaths to limit its own financial liability.
The Fight for Equal Valuation of Victims
Another case highlighting the perceived inadequacy of the infected blood scandal compensation scheme is that of Christopher Thomas, a hemophiliac who died in 1990 at the age of 43. His daughter, Rachel McGuinness, recalled the harrowing final years of his life, which included palliative care at home during a time when HIV carried a massive social stigma.
McGuinness noted that her mother, now 77, has spent more than 30 years grieving her husband while navigating the complexities of the scandal. The revelation that the compensation scheme would not account for the decades of support Thomas would have provided his family was described as a "ridiculous" additional burden. McGuinness expressed disappointment that after waiting decades for an apology and an inquiry, the resulting compensation structure still feels "not fit for purpose."
Advocates argue that the "penalty for dying" is not just a financial issue, but a matter of dignity. Kate Burt, chief executive of the Haemophilia Society, stated that the credibility of the entire scheme rests on the principle that every victim should be valued equally. She argued that the government’s refusal to recognize future financial loss for deceased victims creates a hierarchy of suffering that is "utterly unacceptable."
Administrative Hurdles and the Quest for Justice
The government’s response to these criticisms has been one of cautious deliberation. A spokesperson for the government stated that they are committed to making the system as "fair and compassionate as possible." The administration is currently reviewing responses from a recent consultation period and expects to publish a formal response within 12 weeks of the consultation’s closing.
However, for families who have been campaigning for 40 years, "deliberation" often feels like another delay tactic. The disparity in payouts also extends to the complexity of the application process itself. Families of the deceased often face higher evidentiary standards to prove the link between the contaminated blood and the cause of death, especially when medical records from the 1970s and 80s have been lost, destroyed, or never properly maintained.
Ian Dixon, whose mother-in-law Nora Worthington died in 1993 after receiving a contaminated blood transfusion, highlighted the massive financial gap created by the current rules. He estimated that if Nora were alive today, her compensation would exceed £2 million. Instead, her estate is expected to receive just over £1 million. Dixon emphasized that while the money is significant, the primary issue is the lack of equal recognition for those who "paid the ultimate price."
Broader Implications and Public Trust
The resolution of the infected blood scandal is seen as a litmus test for the British government’s ability to handle large-scale institutional failures. The "penalty for dying" controversy has drawn comparisons to other recent scandals, such as the Post Office Horizon crisis and the Grenfell Tower fire, where victims also accused the state of prioritizing cost-saving over comprehensive justice.
If the government does not address the concerns regarding the infected blood scandal compensation scheme, legal experts suggest it could face a fresh wave of litigation. Some families are already considering judicial reviews of the scheme’s logic, arguing that the exclusion of future financial loss for estates is discriminatory and fails to adhere to the recommendations made by Sir Brian Langstaff in his interim reports.
The Infected Blood Compensation Authority, the body tasked with managing the payouts, has stated its intent to process claims efficiently. However, until the underlying policy regarding deceased victims is amended, the "penalty for dying" will remain a central point of contention between the state and the thousands of families who are still living with the consequences of the NHS’s greatest failure.
As the March 31 deadline for the inquiry’s conclusion approaches, the pressure on the government to revise the scheme continues to mount. For the bereaved, the fight is no longer just about uncovering the truth of what happened decades ago; it is about ensuring that the final act of this long-running tragedy does not involve a further devaluation of the lives lost.
